PT2614832T - Diagnóstico de pré-eclâmpsia - Google Patents

Diagnóstico de pré-eclâmpsia

Info

Publication number
PT2614832T
PT2614832T PT131602757T PT13160275T PT2614832T PT 2614832 T PT2614832 T PT 2614832T PT 131602757 T PT131602757 T PT 131602757T PT 13160275 T PT13160275 T PT 13160275T PT 2614832 T PT2614832 T PT 2614832T
Authority
PT
Portugal
Prior art keywords
preeclampsia
diagnosis
treatment
Prior art date
Application number
PT131602757T
Other languages
English (en)
Portuguese (pt)
Inventor
Hansson Stefan
Akerström Bo
Original Assignee
A1M Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A1M Pharma Ab filed Critical A1M Pharma Ab
Publication of PT2614832T publication Critical patent/PT2614832T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/99—Miscellaneous (1.14.99)
    • C12Y114/99003—Heme oxygenase (1.14.99.3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
PT131602757T 2007-02-12 2008-02-12 Diagnóstico de pré-eclâmpsia PT2614832T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0700339 2007-02-12

Publications (1)

Publication Number Publication Date
PT2614832T true PT2614832T (pt) 2016-10-18

Family

ID=39295873

Family Applications (2)

Application Number Title Priority Date Filing Date
PT87076741T PT2111555E (pt) 2007-02-12 2008-02-12 Diagnóstico de pré-eclâmpsia
PT131602757T PT2614832T (pt) 2007-02-12 2008-02-12 Diagnóstico de pré-eclâmpsia

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT87076741T PT2111555E (pt) 2007-02-12 2008-02-12 Diagnóstico de pré-eclâmpsia

Country Status (18)

Country Link
US (3) US8568999B2 (enExample)
EP (3) EP2613150A1 (enExample)
JP (2) JP5604111B2 (enExample)
KR (2) KR101454013B1 (enExample)
AU (1) AU2008214837B2 (enExample)
BR (1) BRPI0808340A2 (enExample)
CA (1) CA2674204C (enExample)
DK (2) DK2111555T3 (enExample)
EA (2) EA031877B1 (enExample)
ES (2) ES2426069T3 (enExample)
HR (2) HRP20130809T1 (enExample)
HU (1) HUE031613T2 (enExample)
MX (2) MX347788B (enExample)
NZ (1) NZ578077A (enExample)
PL (2) PL2111555T3 (enExample)
PT (2) PT2111555E (enExample)
WO (1) WO2008098734A1 (enExample)
ZA (1) ZA200905101B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA031877B1 (ru) 2007-02-12 2019-03-29 А1М Фарма Аб Применение альфа-1-микроглобулина для профилактики или лечения преэклампсии
DK2638915T3 (en) * 2008-07-18 2017-01-30 A1M Pharma Ab MEDICAL USE OF THE RADICAL BINDER AND ANTIOXIDANT ALFA-1 MICROGLOBULIN
WO2011095981A1 (en) * 2010-02-03 2011-08-11 St. John's Research Institute An in-vitro method for characterizing hemoglobin variant
WO2011116958A1 (en) * 2010-03-24 2011-09-29 Preelumina Diagnostics Ab Hbf and a1m as early stage markers for preeclampsia
US9903865B2 (en) * 2010-03-31 2018-02-27 Sekisui Medical Co., Ltd. Assay, immunochromatographic test strip, and assay reagent kit for measuring an analyte, using a hematocrit correction
US20150004632A1 (en) 2011-10-14 2015-01-01 Aarhus Universitet Diagnostic and prognostic use of prombp-complexes
SG11201500669SA (en) * 2012-09-05 2015-02-27 A1M Pharma Ab Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases
US20140186332A1 (en) * 2012-12-28 2014-07-03 NX Pharmagen Biomarkers of preterm birth
US10928402B2 (en) 2012-12-28 2021-02-23 Nx Prenatal Inc. Treatment of spontaneous preterm birth
AU2016232309A1 (en) 2015-03-16 2017-09-28 A1M Pharma AB. Biomarkers for preeclampsia
KR101732933B1 (ko) 2015-07-29 2017-05-08 영남대학교 산학협력단 신생아의 성장 또는 심혈관계 질환 예후 진단 방법
EP3384076A4 (en) 2015-12-04 2019-09-25 Nx Prenatal Inc. USE OF CIRCULATING MICROPARTICLES TO STRATIFY THE RISK ON A SPONTANEOUS SPRING BIRTH
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
EP4317959A3 (en) * 2018-03-19 2024-03-27 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US11418353B2 (en) * 2019-08-26 2022-08-16 Micron Technology, Inc. Security descriptor generation
CN111626280B (zh) * 2020-04-13 2021-09-07 北京邮电大学 一种无定位点答题卡识别方法和装置
JP7543575B2 (ja) * 2022-09-05 2024-09-02 栄研化学株式会社 遊離ヘモグロビン測定試薬、遊離ヘモグロビン測定方法および抗ヘモグロビン抗体

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1337778A1 (ru) 1984-06-25 1987-09-15 Новосибирский государственный медицинский институт Способ диагностики т жести позднего токсикоза беременных
US5079171A (en) 1988-09-15 1992-01-07 Adeza Biomedical Corporation Determining pregnancy induced hypertension and eclampsia by immunoassay of cellular fibronectin
US5238819A (en) 1988-12-14 1993-08-24 The Regents Of The University Of California Diagnostic assay for the detection of preeclampsia
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5108898A (en) 1989-01-18 1992-04-28 Peters John H Use of fibronectin having a variable included type III repeat sequence as a marker for toxemia in pregnancy
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5166133A (en) 1991-04-17 1992-11-24 Cetus Corporation Method for inhibing adhesion of white blood cells to endothelial cells
US6103691A (en) 1994-03-23 2000-08-15 Tschesche; Harald Utilisation of angiogenin and/or α1 -microglobulin and/or complement factor D in order to inhibit the secretion of proteins
US5849474A (en) * 1995-12-06 1998-12-15 Olson; Camilla M. Diagnosis of preeclampsia in mammals
US5910482A (en) * 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
US6169816B1 (en) * 1997-05-14 2001-01-02 Applied Imaging, Inc. Identification of objects of interest using multiple illumination schemes and finding overlap of features in corresponding multiple images
JP2001348342A (ja) 2001-04-12 2001-12-18 Nippon Zoki Pharmaceut Co Ltd 免疫調整・抗炎症剤
EP1666881B1 (en) 2001-05-04 2010-02-17 Biosite Incorporated Diagnostic markers of acute coronary syndromes and methods of use thereof
ES2284911T3 (es) 2001-09-04 2007-11-16 Iq Corporation B.V. Determinacion y cuantificacion de poblaciones de globulos rojos en muestras.
JPWO2003083479A1 (ja) * 2002-03-29 2005-08-04 松下電器産業株式会社 血液処理方法、血液処理デバイス、ヘモグロビン類測定方法およびヘモグロビン類測定デバイス
DE10237423A1 (de) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
AU2004253471B2 (en) * 2003-06-20 2010-05-13 Raptor Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
AR045074A1 (es) 2003-07-23 2005-10-12 Applied Research Systems Uso de cd164 soluble en desordenes inflamatorios y autoinmunes
JP2007513884A (ja) * 2003-11-26 2007-05-31 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 高められた心血管性リスクのインジケーターとしての尿細管性蛋白尿
WO2005093413A2 (en) 2004-03-22 2005-10-06 Yale University Diagnosis and treatment of preeclampsia
US20070292421A1 (en) * 2005-07-28 2007-12-20 Feinberg Bruce B Method for treating preeclampsia
GB0600916D0 (en) 2006-01-17 2006-02-22 Perkinelmer Instr Las Inc detecting and predicting pre-eclampsia
JP2009524031A (ja) 2006-01-18 2009-06-25 ヴィック、イミュノロジッシェ ダイアグノステック ウー．ベラートゥング カーゲー シリコンに接着するポリペプチドおよび細胞を分析するための試験系
EA031877B1 (ru) 2007-02-12 2019-03-29 А1М Фарма Аб Применение альфа-1-микроглобулина для профилактики или лечения преэклампсии
WO2009108073A1 (en) 2008-02-28 2009-09-03 Auckland Uniservices Limited Biomarkers for prediction of preeclampsia and/or cardiovascular disease
DK2638915T3 (en) 2008-07-18 2017-01-30 A1M Pharma Ab MEDICAL USE OF THE RADICAL BINDER AND ANTIOXIDANT ALFA-1 MICROGLOBULIN
WO2011116958A1 (en) 2010-03-24 2011-09-29 Preelumina Diagnostics Ab Hbf and a1m as early stage markers for preeclampsia

Also Published As

Publication number Publication date
US8568999B2 (en) 2013-10-29
EA031877B1 (ru) 2019-03-29
CA2674204C (en) 2017-07-11
MX2009008408A (es) 2009-11-02
JP2014012670A (ja) 2014-01-23
ES2599003T3 (es) 2017-01-31
PL2111555T3 (pl) 2013-10-31
WO2008098734A1 (en) 2008-08-21
NZ578077A (en) 2012-04-27
MX347788B (es) 2017-05-12
DK2111555T3 (da) 2013-09-02
US10359406B2 (en) 2019-07-23
PT2111555E (pt) 2013-09-04
DK2614832T3 (da) 2016-10-31
ZA200905101B (en) 2012-01-25
JP2010518386A (ja) 2010-05-27
EA201500335A1 (ru) 2016-08-31
US20140065170A1 (en) 2014-03-06
KR20100015315A (ko) 2010-02-12
HRP20161266T1 (hr) 2016-12-16
EA200970758A1 (ru) 2010-02-26
BRPI0808340A2 (pt) 2017-05-30
JP5604111B2 (ja) 2014-10-08
JP5792772B2 (ja) 2015-10-14
CA2674204A1 (en) 2008-08-21
EP2613150A1 (en) 2013-07-10
US20180284087A1 (en) 2018-10-04
KR20140095572A (ko) 2014-08-01
EP2614832A1 (en) 2013-07-17
AU2008214837B2 (en) 2013-01-10
AU2008214837A1 (en) 2008-08-21
EA022609B1 (ru) 2016-02-29
ES2426069T3 (es) 2013-10-21
KR101454013B1 (ko) 2014-11-12
HUE031613T2 (en) 2017-09-28
PL2614832T3 (pl) 2017-01-31
HRP20130809T1 (xx) 2013-10-11
US20100105070A1 (en) 2010-04-29
EP2111555A1 (en) 2009-10-28
KR101608501B1 (ko) 2016-04-04
EP2111555B1 (en) 2013-05-29
EP2614832B1 (en) 2016-07-13

Similar Documents

Publication Publication Date Title
PT2614832T (pt) Diagnóstico de pré-eclâmpsia
IL207360A0 (en) Methods of diagnosing and treating parp - mediated diseases
GB0610867D0 (en) Treatment of pain
EP2170198A4 (en) MEDICAL SYSTEM AND METHOD OF USE
GB0911580D0 (en) Use of one or more cannabinoids in the treatment of epilepsy
GB0922085D0 (en) Cancer diagnosis and treatment
IL210810A0 (en) Compositions for the treatment of pain and/or inflamtion
IL193748A0 (en) Treatment of pain
ZA200806808B (en) Treatment of stressed patients
GB201108964D0 (en) Medicament and method of diagnosis
GB0918392D0 (en) Diagnostic and therapeutic methods
IL213703A (en) Compounds for the treatment of pain and other diseases
GB2465907B (en) VHZ for diagnosis and treatment of cancer
GB0608647D0 (en) Methods of diagnosis and treatment
GB0708452D0 (en) Treatment of nuclear studge
GB0901837D0 (en) Cancer diagnosis and treatment
EP2164494A4 (en) Methods of Treatment
GB0709092D0 (en) Diagnosis and method of disease
GB0723100D0 (en) Treatment of HFnEF
IL216717A0 (en) USE OF BENZYDAMINE IN THE TREATMENT OF p40-DEPENDENT DISEASES
HU0900195D0 (en) Diagnosis and treatment of gluten-induced autoimmune diseases
GB0610868D0 (en) Treatment of pain
GB0714500D0 (en) composition and treatment
GB201017857D0 (en) Methods for diagnosis and methods of treatment
GB0616450D0 (en) Treatment of pain